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Considering hs-cTn as a quantitative rather than qualitative measure will be important, too: the days of a patient being referred to as "troponin positive"
should end, and clinicians should now consider the potential diagnoses seen in the hs-cTn range detected. Finally, determining the appropriate workup for patients with abnormalities in hs-cTn values will be necessary. Yes, there will be more testing and treatment done in these patients, but in theory, thanks to the focus drawn to them through recognition of an abnormal hs-cTn value, such management will likely be more cost-effective given the higher risk status of such patients and may well lead to improved outcomes.
There will be a learning curve as we gain experience with hs-cTnI or T. It is reasonable to expect that the advent of hs-cTn testing will inevitably be accompanied by growing pains; some may call for the simpler paradigm afforded by conventional cTn.
In this case, however, simpler is not better: more rapid and sensitive detection of acute MI coupled with greater prognostic value from hs-cTn testing makes it worth the effort to become acquainted with its use.
